AbbVie acquires Botox-maker Allergan in ‘turning point’ deal

The acquisition will see AbbVie achieve approximately US$30bn in full-year 2020 revenues

AbbVie, the biopharmaceutical company, has acquired Allergan in what its CEO described as an “important milestone”.

The acquisition includes Allergan’s global aesthetics . . .

This is a small extract of the full article which is available ONLY to premium content subscribers. Subscribers sign-in (top right) to read the article.


Subscribe now to premium content on Cosmetics Business